ClinicalTrials.gg
CompletedNCT06249152Updated Jan 20, 2025

Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients

A Phase 2 interventional study of QLS-111, 0.015% and QLS-111, 0.030% in Open-angle Glaucoma (OAG), Ocular Hypertension (OHT) and Glaucoma, sponsored by Qlaris Bio, Inc.. Completed at 1 site in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-01-20.

Sponsored by Qlaris Bio, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2024, 1 year 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 348 studies in Glaucoma, Open-Angle with a site in United States — 49 open to participants now, 67 under way, 5 of them phase 3. Glaucoma, Open-Angle · United States.

Enrollment
210th of 279
36 · median 84
Started
2024
with 9 others
Phase 2
76 of 348
5 open now
Registered
298th of 348
by date

Among the 348 studies in Glaucoma, Open-Angle with a site in United States, this one is the 210th largest by enrollment of the 279 interventional ones that give a count, is one of 10 that started in 2024, is one of 76 in phase 2, and was the 298th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 116 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

49 of the 348 studies in Glaucoma, Open-Angle with a site in United States are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 83 Glaucoma, Open-Angle studies recruiting now, 64 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 348 studies in Glaucoma, Open-Angle with a site in United States, or all of them as a file.
02

Study summary

Qlaris Phase 2 clinical study investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in combination with latanoprost in open-angle glaucoma (OAG) and/or ocular hypertension (OHT) patients.

Read the detailed description

Pilot, double-masked, vehicle-controlled, randomized, prospective parallel study of 14-day once daily evening (QPM) dosing, followed by 14-day twice daily (BID) dosing of an investigational product (IP), QLS-111, or vehicle as concomitant therapy with monotherapy latanoprost a PGA treatment that is administered QPM. Both eyes (OU) will be dosed. The study is comprised of seven (7) visits and approximately 28 days of IP dosing.

03

Conditions studied

  • Open-angle Glaucoma (OAG)
  • Ocular Hypertension (OHT)
  • Glaucoma

Keywords

  • Qlaris
  • OAG
  • Glaucoma
  • PGA therapy
  • Apteryx I
  • OHT
  • latanoprost
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 12 years or older
  • Able and willing provide signed (assent)
  • mild to moderate OAG or OHT in at least one eye and current or previous treatment with PGA. Exhibits decrease (i.e., >20% from reported pre- treatment) in intraocular pressure (IOP). Patient is willing to continue latanoprost throughout the study.
  • IOP ≥19 mmHg at 08:00 hour (H) at qualification visits prior to randomization

Exclusion criteria

Exclusion Criteria:

  • History of active ocular disease other than mild to moderate OAG/OHT
  • Nonresponse to and/or noncompliant with PGA treatment
  • Use of other topical ocular medications with exception of the PGA which the patient will use throughout the study
  • Moderate to severe glaucomatous damage in either eye
  • Previous glaucoma intraocular surgery in either eye (e.g., trabeculectomy, tubes, cyclodestructive procedures, diode) with exception of selective laser trabeculoplasty (SLT) if done less than 12 months from screening, trabecular meshwork minimally invasive glaucoma surgery (MIGS) when combined with cataract surgery and done less than 12 months from screening.
  • significant ocular trauma, or intraocular surgery (e.g., cataract extraction/intraocular lens insertion) or extensive retinal laser treatment, refractive surgery in either eye.
  • Ocular infection, inflammation (e.g., uveitis), moderate to severe blepharitis/meibomitis and/or severe keratoconjunctivitis sicca in either eye at screening, history of herpes simplex keratitis, in either eye.
  • retinal disease in either eye
  • Clinically significant systemic or psychiatric disease
  • Participation in any study within 30 days prior to screening
  • Pregnant or lactating
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Experimental: QLS-111 ophthalmic solution

    Qlaris' IP, QLS-111 ophthalmic solution, provided in 3 concentrations (0.015%, 0.03%, and 0.075%), preservative free (PF), single-use units, masked.

    Drug: QLS-111, 0.015% · Drug: QLS-111, 0.030% · Drug: QLS-111, 0.075%

  • Placebo comparator
    Placebo comparator: Vehicle ophthalmic solution

    Inactive control (0.00%), PF, single-use units, masked.

    Drug: QLS-111 vehicle ophthalmic solution

Interventions

  • QLS-111 eyedrops applied QPM for 14 days the BID for 14 days.

    Also known as: QLS-111

  • QLS-111 eyedrops applied QPM for 14 days the BID for 14 days.

    Also known as: QLS-111

  • QLS-111 eyedrops applied QPM for 14 days the BID for 14 days.

    Also known as: QLS-111

  • DrugQLS-111 vehicle ophthalmic solution

    Vehicle drops applied QPM for 14 days the BID for 14 days.

    Also known as: Vehicle, inactive control

06

What researchers measure

Primary outcomes

  1. Incidence of ocular treatment-emergent adverse events (TEAEs)

    Ocular safety and tolerability

    Time frame: 28 days

  2. Clinically significant change in visual acuity

    Ocular safety and tolerability

    Time frame: 28 days

  3. Clinically significant change in findings on slit lamp exam

    Ocular safety and tolerability

    Time frame: 28 days

  4. Clinically significant change in findings on fundus exam

    Ocular safety and tolerability

    Time frame: 28 days

  5. Incidence of systemic (TEAEs)

    Systemic safety and tolerability

    Time frame: 28 days

  6. Clinically significant change in blood pressure

    Systemic safety and tolerability

    Time frame: 28 days

  7. Clinically significant change in heart rate

    Systemic safety and tolerability

    Time frame: 28 days

Secondary outcomes

  1. Change from baseline (CFB) of mean diurnal IOP in the study eye

    Ocular hypotensive efficacy: diurnal IOP

    Time frame: 28 days

  2. CFB in IOP at various timepoints in the study eye

    Ocular hypotensive efficacy: CFB for multiple timepoints

    Time frame: 28 days

07

Study locations

1 site
  • Berkeley Eye Center
    Houston, Texas 77027, United States
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Dec 2024, 7 months.

Of 38 industry-sponsored phase 2 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 16. This study's 7 months is below that.

Counting every sponsor, half of 41 studies reached it within 11 months; a quarter within 7 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2024
First posted
Feb 8, 2024
StartActual
Apr 21, 2024
Primary completionActual
Dec 20, 2024
CompletionActual
Dec 20, 2024
Last update
Jan 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06249152
Lead sponsor
Qlaris Bio, Inc.
Responsible party
Sponsor
First posted
Feb 8, 2024
Start date
Apr 21, 2024
Primary completion
Dec 20, 2024
Completion
Dec 20, 2024
Last update
Jan 20, 2025

Study contacts

Lisa Brandano
study director · Qlaris Bio, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: QLS-111

Start the discussion